Our initial focus is on perinatal depression.

Perinatal mental health is in crisis—1 in 5 mothers face anxiety or depression, yet too many go undiagnosed. Early detection is critical, but current tools fall short. We’re closing this gap with biomarker-driven precision screening to identify those at risk sooner and enable earlier, more effective intervention.

1 in 5 women will suffer from perinatal depression and anxiety

More than 50% of women with perinatal depression did not have a prior history of depression

More than 600,000 women are affected by perinatal depression and anxiety in the US alone

  • What if we could screen for perinatal depression early in pregnancy?

    What if we could detect perinatal depression before symptoms appear? Early in pregnancy, a simple blood test could identify those at risk, enabling timely intervention and personalised care—transforming outcomes for parents and babies alike.

  • The First Challenge

    Postpartum depression is biologically complex and varies between individuals, making it difficult to predict who will develop it. Without biological markers, treatment remains reactive rather than proactive, delaying support for those who need it most.

  • The Second Challenge

    Screening and diagnosing PPD lacks objective, early detection methods. Current tools rely on self-reported symptoms, often missing those at risk until it’s too late. A biomarker-driven approach can revolutionise screening by providing a precise, early-warning system for intervention.

  • The Third Challenge

    Existing treatments are often a trial-and-error process, with no way to predict who will respond to which therapy. This leads to prolonged suffering and delays in recovery. Biomarker-driven insights can personalise treatment, matching patients with the most effective interventions from the start.

The Future of Mental Health.

  • Discover

    Using blood samples, we decode the molecular signals that shape mental health. Our advanced biomarker analysis uncovers hidden risk factors for PPD, enabling earlier detection and personalised intervention when it matters most.

  • Develop

    We design cutting-edge analytics to identify the most precise and clinically relevant biomarkers. By ensuring accuracy and specificity, we optimise biomarker-driven diagnostics, enhance clinical trial monitoring, and accelerate the development of targeted treatments.

  • Deliver

    Our AI-powered biomarker database transforms mental health care by providing clinicians, patients, and researchers with the most comprehensive insights. By de-risking clinical trials and enabling precision diagnostics, we accelerate the path to better treatments and personalised care.

Learn more about our approach

Mothers deserve care.

Our Values

  1. Innovation for Impact – We push the boundaries of biomarker science and AI to revolutionise mental health diagnostics and treatment.

  2. Precision and Personalisation – We believe in targeted, evidence-based solutions that deliver the right care to the right patients at the right time.

  3. Scientific Excellence – Our work is grounded in rigorous research, cutting-edge technology, and data-driven decision-making.

  4. Patient-Centred Mission – Every discovery is driven by the urgent need to improve lives, starting with perinatal mental health and expanding to all psychiatric disorders.